

The Importance of Pharmacological Synergy in Psychoactive Herbal Medicines

Marcello Spinella, PhD

Abstract

The therapeutic effects of many herbal medicines have been well established; however, definitive mechanisms of action remain to be elucidated for many psychoactive herbal medications. Although several mechanisms have been identified, they are often insufficient to account for the observed effects of the plant or its extracts. This review emphasizes that, in addition to searching for more potent mechanisms, one must consider the additive and supra-additive effects of a plant's multiple constituents. Synergy may occur through pharmacokinetic and/or pharmacodynamic interactions. Examples are given that illustrate synergistic actions in St. John's wort (*Hypericum perforatum*), kava kava (*Piper methysticum*), and valerian (*Valeriana officinalis*).

(*Altern Med Rev* 2002;7(2):130-137)

Introduction

Determining the pharmacological mechanisms of herbal medicines presents certain challenges distinct from the study of synthetic drugs. For example, synthetic drugs are studied in isolation; whereas, herbal medicines often contain multiple active substances that act in combination.

A single drug may have several pharmacological actions, but it is only those that occur in concentrations reached by standard doses that are considered relevant. In many cases, it may be a single action that is believed to account for its effects. For example, caffeine has multiple actions, but only antagonism of adenosine receptors occurs at normally-reached concentrations.¹ Some psychoactive herbal medicines have had several of their chemical constituents identified. Although

a plant may contain the appropriate constituents, they may be in insufficient amounts to account for the observed effects. Pharmacological synergy should also be investigated to explain the actions of an herbal medicine. Significant interactions may occur which are not evident when single constituents are studied in isolation. In other cases, a predominant mechanism may be potentiated by lesser mechanisms. Thus, some herbal medications may produce a more favorable response when an extract is given versus an isolated single constituent. However, the advantages of single constituents versus extracts should be considered on a case-by-case basis.

Mechanisms of Synergy

Two broad types of synergy can be distinguished, based on the nature of the interaction: pharmacodynamic or pharmacokinetic. Pharmacodynamic synergy results from two drugs directed at a similar receptor target or physiological system. For example, combinations of allosteric modifiers at the gamma-aminobutyric acidA (GABA_A) receptor create potent synergistic interactions.²⁻⁴ Pharmacokinetic synergy results from the processes of drug absorption, distribution, biotransformation, or elimination. For example, combined administration of drugs which compete for albumin binding will elevate the free drug concentrations, and thus potentiate their actions.⁵

Marcello Spinella, PhD – Assistant professor of psychology, Richard Stockton College of New Jersey; postdoctoral training in clinical neuropsychology; research on the neuropharmacology of analgesia.
Correspondence address: Division of Social and Behavioral Sciences, Richard Stockton College of New Jersey, P.O. Box 195, Pomona, NJ 08240. E-mail: marcello.spinella@stockton.edu

St. John's Wort

St. John's wort (*Hypericum perforatum*) is traditionally known for treatment of depression, insomnia, and anxiety. A large body of animal and human clinical research supports its antidepressant effects.⁶⁻¹⁰


Pharmacodynamic Synergy

Several classes of chemical constituents of St. John's wort have been identified: naphthodianthrones, flavonoids, phloroglucinols, phenolic acids, xanthenes, and terpenes (Figure 1).^{11,12} The naphthodianthrone hypericin, flavonols, and xanthenes have been shown to inhibit both monoamine oxidase (MAO) and/or catechol-o-methyltransferase (COMT).¹³⁻¹⁶ While some pharmaceutical antidepressants significantly inhibit MAO, St. John's wort extracts only do so in millimolar concentrations; therefore, this mechanism appears inadequate to explain the full antidepressant effect of the herb.

The phloroglucinol hyperforin is a reuptake inhibitor of serotonin, norepinephrine, and dopamine in the nanomolar range.¹⁷ Radio-labeled hyperforin crosses the blood-brain barrier and penetrates brain tissue.¹⁸ Human and animal studies support hyperforin as an essential and perhaps sufficient element for antidepressant effects of St. John's wort.^{6,7,19}

While hyperforin may be sufficient to explain the antidepressant effects of St. John's wort, synergistic effects on monoamines is possible.²⁰ Combined reuptake and enzyme inhibition can similarly be seen with conventional antidepressants (MAO inhibitors, tricyclic antidepressants, and selective serotonin reuptake inhibitors) to potentiate each other's effects in cases of treatment-resistant depression.^{21,22} This must be done with caution, selecting the appropriate drugs and doses, to avoid an overdose and serotonin syndrome. In the case of St. John's wort, however, effects which are individually sub-therapeutic (i.e., MAO and COMT inhibition) may combine to

Figure 1. Chemical Structures of Hypericin and Hyperforin




augment the primary pharmacological mechanism (monoamine reuptake inhibition).

Pharmacokinetic Synergy

Pharmacokinetic synergy may also occur with St. John's wort, where a combination of constituents improves its oral bioavailability. An

extract containing naphthodianthrones is inactive in a water suspension, but very effective when another constituent, procyanidin, is present. Procyanidin increases the water solubility of naphthodianthrones, thus increasing their pharmacokinetic availability.⁸

Figure 2. The Major Kava Lactones



Kava Kava

Kava kava (*Piper methysticum*) is a plant native to the South Pacific islands with anxiolytic and sedative effects.²³ Controlled human clinical studies show it to be superior to placebo for treatment of anxiety, and equivalent in efficacy to the benzodiazepine oxazepam (Serax®).^{24,25}

The active chemical constituents from kava are the kava lactones, principally kavain, dihydrokavain, yangonin, dimethoxyyangonin, methysticin, and dihydromethysticin (Figure 2).²³ Kava lactones pass the blood-brain barrier and behavioral effects occur at micromolar concentrations.^{25,26}

Kava lactones enhance binding to the GABA_A receptor in the low micromolar range, through a non-benzodiazepine mechanism.^{27,28} Kava lactones also block voltage-gated Na⁺ and Ca²⁺ channels in micromolar concentrations.²⁹⁻³¹ Further, kava lactones interact with monoamine systems by blocking the reuptake of norepinephrine and inhibiting MAO_B.^{32,33}

Pharmacodynamic Synergy

The central nervous system depressant effects of kava lactones occur through actions on GABA_A and Na⁺ and Ca²⁺ channels, which occur at normally-reached concentrations. Combined kava lactones, kavain and dihydromethysticin, act in an additive manner to inhibit Ca²⁺ channels.³⁴ However, combined GABAergic and Na⁺/Ca²⁺ channel inhibition are likely to produce additive or synergistic depressant effects. For example, pharmaceutical Ca²⁺ channel blockers potentiate the sedative effects of benzodiazepines.³⁵ Ethanol and barbiturates are also noted to potentiate the sedative and cognitive-impairing effects of kava.^{28,36,37}

The monoamine actions of kava may also contribute to its therapeutic effects. Monoamine mechanisms are more commonly associated with antidepressants, but they can be effective in treating generalized anxiety.^{38,39} Kava lactone actions on norepinephrine reuptake and MAO_B are individually less potent than pharmaceutical antidepressants, but their combination may potentiate each other's effects.

Pharmacokinetic Synergy

Administering combined kava lactones allows for greater access to the brain than when they are given individually.²⁶ For example, yangonin given with other kava lactones (administered i.p.) reaches levels 20 times higher in the brain than when it is given alone. Similarly, kavain levels in the brain are doubled when given in combination with other kava lactones, compared to levels reached when given alone. The reason for this pharmacokinetic synergy is not certain. One possibility is that kava lactones are competing for plasma binding sites. Thus, giving them in combination occupies more plasma binding sites, allowing for greater free plasma concentrations of the remaining kava lactones. With higher plasma concentrations, there is greater access to the brain. Another possible reason for this pharmacokinetic synergy is that administering combined kava lactones improves intestinal absorption. While yangonin and desmethoxyyangonin are ineffective orally when given alone, they increase the potency of a combination of kava lactones.⁴⁰


Valerian

Valerian (*Valeriana officinalis*) has a traditional reputation for treating anxiety, insomnia, and seizures.^{41,42} Animal studies of valerian support it as a central nervous system depressant.⁴³⁻⁴⁷ Studies in humans demonstrate that valerian extracts increase slow wave sleep, improve sleep quality, and decrease sleep latency.⁴⁸⁻⁵² Valerian's main chemical constituents are categorized as monoterpenes and sesquiterpenes (Figure 3).⁴³

Pharmacodynamic Synergy

Several GABAergic mechanisms of action have been proposed for valerian. There is some debate whether oral valerian reverses uptake of GABA. In support of this, low microgram concentrations of an aqueous valerian extract inhibit uptake and stimulate release of GABA from synaptosomes.^{53,54} This effect is Na⁺-dependent and Ca²⁺-independent, suggesting it is due to reversal of the neuronal GABA transporter. Some researchers report GABA is present in valerian, which

Figure 3. Some Constituents of Valerian



could account for these results.⁵⁵ If so, this does not explain the effects of oral valerian, since GABA does not readily cross the blood-brain barrier. However, other researchers have failed to find GABA in valerian preparations, so reversal of reuptake may still be considered a possible mechanism of valerian's sedative effects.⁵⁶

There is additional evidence for other GABAergic effects of valerian. For example, valerenic acid inhibits enzymatic breakdown of GABA, and low concentrations of valerian extracts enhance benzodiazepine binding at the GABA_A receptor ([³H]flunitrazepam).^{43,56,57} Ortiz and colleagues found there are at least two constituents of valerian acting at the GABA_A receptor.⁵⁶ Valerian extracts also potentiate the behavioral actions of barbiturates.⁴⁷ It is not clear which of these GABA mechanisms account for valerian's effects, but additive or synergistic interactions are likely, especially since they all affect GABAergic transmission.

Conclusions

There are multiple examples of pharmacodynamic and pharmacokinetic synergy at work in psychoactive herbal medicines (Table 1). St. John's wort shows evidence of pharmacodynamic synergy through monoamine neurotransmitter systems, preventing neurotransmitter breakdown, and blocking reuptake. Pharmacokinetic synergy is evident in St. John's wort since procyanidin increases the bioavailability of the naphthodianthrones. Kava kava's effects on GABA and voltage-gated ion channels (and possible monoamine systems) create pharmacodynamic synergy. Kava kava also shows evidence of pharmacokinetic synergy since administration of combined kava lactones in-

creases brain bioavailability of each, compared to individual administration. Valerian shows evidence of pharmacodynamic synergy since multiple constituents of the herb are acting on GABAergic systems, both pre- and post-synaptically. Pharmacokinetic synergy in valerian is possible, but has not yet been investigated.

The above examples of synergy are directly relevant to the therapeutic benefits of these herbal medicines. The synergistic effects of St. John's wort likely enhance its effects on monoamine neurotransmitter systems, the predominant mechanism of most antidepressant drugs. The synergistic interactions of kava kava occur through GABA, voltage-gated ion channel, and monoamine systems. All of these mechanisms help account for kava kava's demonstrated anti-anxiety effects. Finally, the synergistic effects of valerian's constituents on GABA transmission would explain its demonstrated effects on sleep.

Table 1. Summary of Synergistic Mechanisms

| | Pharmacodynamic Synergy | Pharmacokinetic Synergy |
|-----------------|--|--|
| St. John's Wort | Monoamine reuptake inhibition; MAO inhibition; COMT inhibition | Procyanidin increases bioavailability of hypericin |
| Kava kava | GABAA facilitation; Na ⁺ and Ca ²⁺ -channel inhibition; MAO inhibition; Reuptake inhibition of NE | Kavalactones increase each other's bioavailability |
| Valerian | Multiple GABA mechanisms | Not yet investigated |

The above examples illustrate that synergistic mechanisms should at least be considered when searching for the mechanisms of action of a psychoactive herbal medication. In any given case, a sole mechanism may be in effect, or there may be complex interactions among active constituents. Since the effects of interest are often obtained by using the whole herb or extract, it is important to understand the effects of active constituents in combination as well as in isolation. Since herbal medicines are most commonly used as a whole-herb or extract, these are the preparations we should seek to explain.

References

- Snyder SH, Sklar P. Behavioral and molecular actions of caffeine: focus on adenosine. *J Psychiatr Res* 1984;18:91-106.
- DeLorey TM, Kissin I, Brown P, Brown GB. Barbiturate-benzodiazepine interactions at the gamma-aminobutyric acidA receptor in rat cerebral cortical synaptoneurosomes. *Anesth Analg* 1993;77:598-605.
- van Steveninck AL, Gieschke R, Schoemaker HC, et al. Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. *Psychopharmacology (Berl)* 1993;110:471-478.
- Vanover KE, Suruki M, Robledo S, et al. Positive allosteric modulators of the GABA(A) receptor: differential interaction of benzodiazepines and neuroactive steroids with ethanol. *Psychopharmacology (Berl)* 1999;141:77-82.
- Schoener EP. Mechanisms of depressant drug action/interaction. *Recent Dev Alcohol* 1986;4:39-60.
- Chatterjee SS, Bhattacharya SK, Wonnemann M, et al. Hyperforin as a possible antidepressant component of hypericum extracts. *Life Sci* 1998;63:499-510.
- Chatterjee SS, Noldner M, Koch E, Erdelmeier C. Antidepressant activity of *Hypericum perforatum* and hyperforin: the neglected possibility. *Pharmacopsychiatry* 1998;31:7-15.
- Butterweck V, Wall A, Lieflander-Wulf U, et al. Effects of the total extract and fractions of *Hypericum perforatum* in animal assays for antidepressant activity. *Pharmacopsychiatry* 1997;30:117-124.
- Kim HL, Streltzer J, Goebert D. St. John's wort for depression: a meta-analysis of well-defined clinical trials. *J Nerv Ment Dis* 1999;187:532-538.
- Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression – an overview and meta-analysis of randomised clinical trials. *BMJ* 1996;313:253-258.

11. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of *Hypericum perforatum* L. *Pharmacopsychiatry* 1997;30:129-134.
12. Erdelmeier CA. Hyperforin, possibly the major non-nitrogenous secondary metabolite of *Hypericum perforatum* L. *Pharmacopsychiatry* 1998;31:2-6.
13. Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract. *J Geriatr Psychiatry Neurol* 1994;7:S57-S59.
14. Muller WE, Rolli M, Schafer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. *Pharmacopsychiatry* 1997;30:102-107.
15. Thiede HM, Walper A. Inhibition of MAO and COMT by Hypericum extracts and hypericin. *J Geriatr Psychiatry Neurol* 1994;7:S54-S56.
16. Rocha L, Marston A, Kaplan MA, et al. An antifungal gamma-pyrone and xanthenes with monoamine oxidase inhibitory activity from *Hypericum brasiliense* *Phytochemistry* 1994;36:1381-1385.
17. Muller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. *Pharmacopsychiatry* 1998;31:16-21.
18. Ostrowski E. Investigational analysis, ¹⁴C-labeling, and pharmacokinetics of phenolic contents of *Hypericum perforatum* L. Doctoral Dissertation. University of Marburg, Germany; 1988. [Article in German]
19. Laakmann G, Schule C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. *Pharmacopsychiatry* 1998;31:54-59.
20. Bennett DA Jr, Phun L, Polk JF, et al. Neuropharmacology of St. John's wort (Hypericum). *Ann Pharmacother* 1998;32:1201-1208.
21. Amsterdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. *Depress Anxiety* 1997;5:84-90.
22. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. *Clin Pharmacokinet* 1996;31:444-469.
23. Lebot V, Merlin M, Lindstrom L. *Kava – The Pacific Elixir: The Definitive Guide to its Ethnobotany, History, and Chemistry*. Rochester, VT: Healing Arts Press; 1997.
24. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. *J Clin Psychopharmacol* 2000;20:84-89.
25. Lindenberg D, Pitule-Schodel H. D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness. *Fortschr Med* 1990;108:49-50, 53-54. [Article in German]
26. Keledjian J, Duffield PH, Jamieson DD, et al. Uptake into mouse brain of four compounds present in the psychoactive beverage kava. *J Pharm Sci* 1988;77:1003-1006.
27. Boonen G, Haberlein H. Influence of genuine kavapyrone enantiomers on the GABA-A binding site. *Planta Med* 1998;64:504-506.
28. Jussofie A, Schmitz A, Hiemke C. Kavapyrone enriched extract from *Piper methysticum* as modulator of the GABA binding site in different regions of rat brain. *Psychopharmacology (Berl)* 1994;116:469-474.
29. Friese J, Gleitz J. Kavain, dihydrokavain, and dihydromethysticin non-competitively inhibit the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated Na⁺ channels. *Planta Med* 1998;64:458-459.
30. Gleitz J, Tosch C, Beile A, Peters T. The protective action of tetrodotoxin and (+/-)-kavain on anaerobic glycolysis, ATP content and intracellular Na⁺ and Ca²⁺ of anoxic brain vesicles. *Neuropharmacology* 1996;35:1743-1752.
31. Ferger B, Boonen G, Haberlein H, Kuschinsky K. *In vivo* microdialysis study of (+/-)-kavain on veratridine-induced glutamate release. *Eur J Pharmacol* 1998;347:211-214.
32. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. *Planta Med* 1997;63:548-549.
33. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from *Piper methysticum* Forster (kava-kava). *Pharmacopsychiatry* 1998;31:187-192.
34. Walden J, von Wegerer J, Winter U, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. *Prog Neuropsychopharmacol Biol Psychiatry* 1997;21:697-706.

35. Takahashi H, Yoshimoto M, Higuchi H, et al. Different effects of L-type and T-type calcium channel blockers on the hypnotic potency of triazolam and zolpidem in rats. *Eur Neuropsychopharmacol* 1999;9:317-321.
36. Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. *Clin Exp Pharmacol Physiol* 1990;17:509-514.
37. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. *Drug Alcohol Rev* 1997;16:147-155.
38. Boerner RJ, Moller HJ. The importance of new antidepressants in the treatment of anxiety/depressive disorders. *Pharmacopsychiatry* 1999;32:119-126.
39. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. *Arch Gen Psychiatry* 1993;50:884-895.
40. Meyer HJ. *Ethnographical Search for Psychoactive Drugs: Pharmacology of Kava*. Efron DH, ed. New York, NY: Raven; 1967:133-140.
41. Temkin O. *The Falling Sickness: A History of Epilepsy from the Greeks to the Beginnings of Modern Neurology*. Baltimore: Johns Hopkins Univ Press; 1971.
42. Tyler V. *Herbs of Choice*. New York: Pharmaceutical Products Press; 1994.
43. Houghton PJ. The biological activity of valerian and related plants. *J Ethnopharmacol* 1988;22:121-142.
44. Hölzl J, Fink C. Effect of valeprotriate on spontaneous motor activity in mice. *Arzneimittelforschung* 1984;34:44-47. [Article in German]
45. Della Loggia R, Tubaro A, Redaelli C. Evaluation of the activity on the mouse CNS of several plant extracts and a combination of them. *Riv Neurol* 1981;51:297-310. [Article in Italian]
46. Leuschner J, Müller J, Rudmann M. Characterisation of the central nervous depressant activity of a commercially available valerian root extract. *Arzneimittelforschung* 1993;43:638-641.
47. Dunaev VV, Trzhetsinskii SD, Tishkin VS, et al. Biological activity of the sum of the valepotriates isolated from *Valeriana alliariifolia*. *Farmakol Toksikol* 1987;50:33-37. [Article in Russian]
48. Gessner B, Klasser M. Studies on the effect of Harmonicum Much on sleep using polygraphic EEG recordings. *EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb* 1984;15:45-51. [Article in German]
49. Schulz H, Stolz C, Müller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. *Pharmacopsychiatry* 1994;27:147-151.
50. Lindahl O, Lindwall L. Double blind study of a valerian preparation. *Pharmacol Biochem Behav* 1989;32:1065-1066.
51. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. *Planta Med* 1985;Apr:144-148.
52. Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root (*Valeriana officinalis* L.) improves sleep quality in man. *Pharmacol Biochem Behav* 1982;17:65-71.
53. Santos MS, Ferreira F, Cunha AP, et al. An aqueous extract of valerian influences the transport of GABA in synaptosomes. *Planta Med* 1994;60:278-279.
54. Santos MS, Ferreira F, Cunha AP, et al. Synaptosomal GABA release as influenced by valerian root extract – involvement of the GABA carrier. *Arch Int Pharmacodyn Ther* 1994;327:220-231.
55. Santos MS, Ferreira F, Faro C, et al. The amount of GABA present in aqueous extracts of valerian is sufficient to account for [3H]GABA release in synaptosomes. *Planta Med* 1994;60:475-476.
56. Ortiz JG, Nieves-Natal J, Chavez P. Effects of *Valeriana officinalis* extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. *Neurochem Res* 1999;24:1373-1378.
57. Riedel E, Hansel R, Ehrke G. Inhibition of gamma-aminobutyric acid catabolism by valerianic acid derivatives. *Planta Med* 1982;46:219-220. [Article in German]